Arthroleve formulation patent filed

By Clarisse Douaud

- Last updated on GMT

Related tags: Osteoarthritis

University Lab Technologies has filed a patent for its product
Arthroleve, in the first of several said for products in its
pipeline.

The one-year-old Florida-based company developed Arthroleve through a combination of three ingredients it said provide significant relief from arthritic pain.

Like many nutraceutical companies in the area of joint health, University Lab Technologies said it is placing its product as a potential to fill the shoes once filled by pharmaceutical Vioxx now removed from the market.

Currently the marketplace for nutraceutical arthritis products is dominated by products containing primarily glucosamine, then chondroitin sulfate or MSM (methylsulfonylmethane).

"Our product contains an entirely different set of ingredients geared to relieving the symptoms of arthritis,"​ Dr. Jarret Morrow, president and chief scientific officer for University Lab Technologies, told NutraIngredients-USA.

Arthroleve is formulated of natural compounds including s-adenosyl methionine (SAMe), glucosamine sulfate and devil's claw extract.

University Lab Technologies is planning clinical trials on its formulation, but to date it has based the intended results of Arthroleve on the literature pointing to the benefits of each individual ingredient for arthritis support.

Since Vioxx was withdrawn, nutraceutical players have scrambled to develop new products to fill the void left by the pharmaceutical.

"The withdrawal of such blockbuster pharmaceutical products such as Vioxx and Celebrex has left millions of patients without a safe alternative for the relief of arthritic pain,"​ said Dr. Morrow. "We feel that this represents an incredible opportunity for the launch of our patent-pending, revolutionary Arthroleve product."

Dr. Morrow began developing Arthroleve one year prior to founding University Lab Technologies. The company is lined with a distributor to beginning marketing the nutraceutical nationwide within the next two months according to Dr. Morrow.

According to the Arthritis Foundation, one in three Americans - almost 66 million individuals - suffer from daily joint discomfort, representing a massive opportunity for companies that can provide them with safe respite. Arthritis represents the number one condition for which patients seek alternatives to prescription and over the counter pharmaceutical pain medication.

Related topics: Regulation, Bone & joint health

Related news

Show more

Related products

show more

Vitamin K2 Amplifies Vitamin D3’s Impact

Vitamin K2 Amplifies Vitamin D3’s Impact

NattoPharma – Gnosis by Lesaffre | 06-Sep-2021 | Data Sheet

Few vitamins work better together than Vitamins K2 and D3. Both fat-soluble vitamins play a central role in how the body utilizes calcium, synergistically...

Absocurcumin® - A Botanic Joint Health Ingredient

Absocurcumin® - A Botanic Joint Health Ingredient

BOTANIC HEALTHCARE (NZ) LTD | 02-Sep-2021 | Clinical Study

ABSOCURCUMIN® is a clinically proven standardized phytochemical composition derived from Turmeric, Curcuma longa. In a controlled study of 30 adults aged...

It’s time to redefine mobility

It’s time to redefine mobility

BIOIBERICA, S.A.U. | 13-Jul-2021 | Insight Guide

At Bioiberica, we’re tapping into the demand for holistic health solutions with a new identity for our Healthcare branded ingredients – starting with mobility....

Related suppliers

Follow us

Products

View more

Webinars